Twelve Studies Presented at ASM 2014 Highlight New Performance and Clinical Outcome Data Using Select Verigene Infectious

Twelve Studies Presented at ASM 2014 Highlight New Performance and Clinical Outcome Data Using Select Verigene Infectious Disease Tests  NORTHBROOK, Ill., May 21, 2014 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that twelve studies evaluating the performance and clinical impact of select Verigene® multiplex infectious disease tests have been presented at the 114^th General Meeting of the American Society for Microbiology (asm2014), held this week in Boston, Massachusetts.  In addition, during the meeting Nanosphere showcased Faces of Sepsis™, a video recently launched by Sepsis Alliance, a non-profit patient advocacy organization, which provides a glimpse into the touching stories of three people whose lives have been affected by sepsis. This video was produced in part with unrestricted support from Nanosphere.  "Antibiotic-resistant bacteria pose a serious threat to human and economic health in the U.S., and significantly complicate the effective treatment of life-threatening infectious diseases like sepsis," said Michael McGarrity, president and chief executive officer of Nanosphere. "We believe our menu of Verigene bloodstream infection tests offers a powerful solution to this growing healthcare challenge, and are pleased with the growing body of clinical evidence that demonstrates the critical impact they can have on the quality of patient care and antimicrobial stewardship efforts in hospitals."  Following are summaries of several of the studies presented. Abstracts for the remaining posters can be found at    *Poster 1141: "De-escalation of Antibiotics in Response to the Nanosphere     Verigene Gram-Positive Blood Culture Assay." This study compared patient     results and treatment before and after the Verigene Gram-Positive Blood     Culture Test (BC-GP) was implemented along with an automated result     reporting algorithm that included antibiotic recommendations for the     treating doctors. The test led to a 26 hour reduction in the time from     sample collection to the first dose of appropriate antibiotics for     patients with methicillin-sensitive Staphylococcus aureus (MSSA) and     vancomycin-resistant Enterococcus (VRE) infections. Additionally, the     percentage of patients placed on targeted therapy within 3 days of     collection increased from 62.8% in the pre-implementation group to 81.5%     in the post-BC-GP implementation group. The study was conducted at Baylor     University Medical Center and med fusion Laboratory (Dallas and     Lewisville, TX), led by Dr. S. Beal.   *Poster 1145: "Comparison of Verigene BC-GP to Peptide Nucleic Acid     Fluorescence in situ Hybridization (PNA-FISH) in Conjunction with mecA     Gene Detection for Staphylococcus aureus Bacteremia." In this study, each     of the 79 S. aureus isolates evaluated was correctly identified by both     Verigene BC-GP and PNA-FISH. Verigene BC-GP accurately distinguished     methicillin-resistant S. aureus (MRSA) from MSSA in all cases, while mecA     gene detection correctly distinguished 78 of 79 cases. Time to pathogen     identification and methicillin resistance determination was shortest by     Verigene BC-GP and both molecular methods provided more rapid results than     the phenotypic method, leading the authors to conclude that use of     Verigene BC-GP may lead to improved antibiotic use in patients with S.     aureus bacteremia compared to other platforms. The study was conducted at     Intermountain Healthcare (Salt Lake City, UT), led by Dr. B. K. Lopansri.   *Poster 1566: "Evaluation of the Nanosphere Verigene BC-GN for the     Identification of Gram-Negative Bacilli and Detection of Antibiotic     Resistance Mechanisms Directly from Positive Blood Cultures." In this     study, the Verigene Gram-Negative Blood Culture Test (BC-GN) correctly     identified 100% of gram-negative bacteria in 33 blood cultures and     correctly identified 13 out of 14 carbapenemase resistance markers.     Verigene BC-GN decreased the time to bacterial identification by a range     of 12 hours 21 minutes to 48 hours 18 minutes when compared to     conventional culture methods. In addition, review showed that medical     management could have been modified for 7 of 22 patients and the     antibiotic change could have been made by an average of 33 hours 26     minutes sooner as compared to acting on the results of conventional     culture identification. The study was conducted at Kaiser Permanente     Northwest (Portland, OR), led by J.T. Hill.   *Poster 1568: "Performance of the Nanosphere Verigene BC-GN Assay in an     Acute Care Inner-City Hospital." Verigene BC-GN successfully identified     the causative pathogen in 100% of the 65 patient cases tested in this     study. All resistance determinants were correctly identified based on     phenotypic and molecular comparison. In addition, Verigene BC-GN detected     organisms that produce the resistance enzyme CTX-M extended-spectrum     beta-lactamase (ESBL) in 3% of isolates tested, and identified 1 isolate     of Enterobacter species as an ESBL producer that would have otherwise gone     undetected by the laboratory. These results led the study authors to     conclude that Verigene BC-GN has the potential to detect ESBL and     carbapenem resistance determinants routinely encountered at their     institution. The study was conducted at Hennepin County Medical Center     (Minneapolis, MN), led by Dr. G. Hansen.   *Poster 1588: "Effects of Blood Volume on the Performance of the Verigene     BC-GP Assay in Pediatric Patients." For the 136 pediatric blood cultures     tested, Verigene BC-GP correctly identified 123 blood culture bottles with     mean blood volume of 1.5 milliliters (mL). For this data set, 93.8% of the     bottles containing greater than 3 mL of blood and 90.0% of bottles with     blood volume of less than 3 mL were successfully identified by Verigene     BC-GP. The 13 discordant results had blood culture bottles with a mean     blood volume of 1.7 mL. The authors conclude that obtaining adequate blood     volume is an ongoing challenge for the detection of pathogens in     bloodstream infections in pediatric patients; however, Verigene BC-GP is     highly robust with blood volume having no impact on overall performance     and blood volume. The study was conducted at Children's Hospital of Los     Angeles, led by Dr. C. M. Polanco.   *Poster 2533: "Decreasing Turnaround Times in Septic Patients Infected with     Carbapenemase Producing Gram-Negative Organisms, a First Look at an     Emerging Technology." In this study, sensitivity and specificity of     Verigene BC-GN were both 100% for each of the following organisms and     carbapenemase-encoding genes: bla[OXA23 ]containing A. baumannii, bla[VIM]     containing C. freundii, bla[NDM-1], bla[CTX-M-1 ]containing ATCC BAA2147     K. pneumoniae, bla[KPC ]containing E. cloacae, bla[KPC ]containing E.     coli, and bla[IMP ]containing K. pneumoniae[. ]The study was conducted at     San Antonio Military Medical Center (Fort Sam Houston, TX), led by E.     Steele.  About the Verigene® System  The Verigene System uses Nanosphere's core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. Currently, the multiplexed Verigene assays target infections of the blood, respiratory tract and gastrointestinal tract. The information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy, and reduced spread of antibiotic resistance.  About Nanosphere, Inc.  Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at  CONTACT: Investors:          Roger Moody, Chief Financial Officer          847-400-9021                   Michael Rice, LifeSci Advisors          646-597-6979                   Media:          Lindsey Saxon, Director of Communications          847-400-9173  
Press spacebar to pause and continue. Press esc to stop.